Navigation Links
Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors

NEW YORK, May 14, 2013 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("ITI"), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, is pleased to announce the appointment of Professor Sir Michael Rawlins , MD, FRCP, FMedSci, to its board of directors.  Sir Michael is an internationally respected figure in the field of drug safety, clinical effectiveness and cost effectiveness having been Chairman of the UK's National Institute for Clinical Excellence (NICE) from 1999 (at its inception) through March 2013.  NICE provides guidance to the UK's National Health Service (NHS) on whether new or existing pharmaceutical products should be made available to patients covered under the NHS and also develops clinical guidelines for patient care by NHS professionals.  Recently, Sir Michael assumed the Presidency of the UK's Royal Society of Medicine, a center for education and scholarship both in the UK and globally.  Sir Michael had a distinguished career as professor of clinical pharmacology and a general physician at the University of Newcastle upon Tyne.  He is the recipient of numerous honors over the years, such as the Hutchinson Medal in 2003, the Galen Medal in 2010, and the Prince Mahidol Award for Medicine in 2012.  He was appointed Knight Bachelor in 1999.

"We are excited to have Sir Michael Rawlins join our board," stated Sharon Mates , Ph.D., Chairman and Chief Executive Officer of Intra-Cellular Therapies.  "His expertise in the cost-effectiveness of new pharmaceuticals and other issues in health economics will be invaluable to Intra-Cellular Therapies.  I look forward to working closely with Michael as we transition our clinical programs through late-stage development and commercial approval."

"I am delighted to join the ITI Board of Directors.  It comprises a group of individuals who have made significant contributions to the advancement of medical science, biotech entrepreneurship and the development of drugs serving unmet medical needs," said Sir Michael.  "ITI has set itself on a course to develop outstanding new pharmaceuticals to treat CNS diseases, surely an ambitious task, but one in which I am pleased to join and help."


ITI-007 is the Company's first-in-class antipsychotic with a unique mechanism of action.  ITI-007 combines potent 5-HT2A receptor antagonism with dopamine receptor phosphoprotein modulation (DPPM) and serotonin reuptake inhibition for the treatment of acute and residual schizophrenia.  At dopamine D2 receptors, ITI-007 has dual properties acting as a post-synaptic antagonist and as a pre-synaptic partial agonist.  ITI-007 also stimulates phosphorylation of glutamatergic NMDA NR2B receptors in a mesolimbic specific manner.  This regional selectivity in brain areas thought to mediate the efficacy of antipsychotic drugs together with serotonergic, glutamatergic, and dopaminergic interactions is expected to result in superior antipsychotic efficacy for positive, negative, affective and cognitive symptoms associated with schizophrenia.  The serotonin reuptake inhibition allows for additional antidepressant efficacy for the treatment of schizoaffective disorder, co-morbid depression, and/or as a stand-alone treatment for major depressive disorder (MDD).  ITI-007 is currently in a Phase II clinical trial in schizophrenia.  We believe ITI-007 will be useful for the treatment of behavioral disturbances in dementia, autism and other CNS diseases and well as in bipolar disorder and other psychiatric and neurodegenerative disorders.


Intra-Cellular Therapies (ITI) is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disease and other disorders of the Central Nervous System (CNS).  The Company is studying the efficacy of ITI-007 for the treatment of acutely-exacerbated schizophrenia in a large Phase II, multicenter clinical trial.  This Phase II trial follows a favorable Phase I/II study demonstrating the safety and tolerability of ITI-007 across a broad range of doses in patients with stable schizophrenia.  In the Phase I/II trial, exploratory clinical measures revealed signals consistent with antipsychotic efficacy for positive and negative symptoms and antidepressant efficacy for ITI-007.  In February 2011, ITI entered into a collaboration with the Takeda Pharmaceutical Company to develop phosphodiesterase 1 (PDE1) inhibitors for the treatment of cognitive deficits in schizophrenia and other CNS disorders.  Recently, ITI announced the successful completion of a Phase I single rising dose study of its PDE1 inhibitor, ITI-214.  ITI has additional programs in the areas of Parkinson's disease, Alzheimer's disease, depression, and cardiovascular disease.

Allen A. Fienberg , Ph.D.
Vice President
Business Development of Intra-Cellular Therapies, Inc.

Burns McClellan, Inc.
Angeli Kolhatkar (Investors)
Justin Jackson (Media)
Phone +1 (212) 213-0006

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
2. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
3. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
4. BioRestorative Therapies Retains KCSA Strategic Communications as Investor Relations Counsel
5. BioRestorative Therapies Obtains $2.1 Million in 2012 Private Financing
6. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
7. BioRestorative Therapies Announces Next Generation of Stem Cell Disc Delivery Device
8. CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies
9. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
10. CSL Biotherapies Awarded US Government Contract for Influenza Pandemic Preparedness and Response
11. Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics (AMA), ... MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View (FPV) racing ... AMA members have embraced this type of racing and several new model aviation pilots ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation Technologies would like ... to Deloitte's 2015 Technology Fast 500 list of the fastest growing companies in ... Class II medical device that speeds up orthodontic tooth movement by as much ...
(Date:11/24/2015)... INCLINE VILLAGE, Nev. , Nov. 24, 2015  PDL ... John P. McLaughlin , the company,s president and chief ... Piper Jaffray Healthcare Conference next week in New ... and will occur on Tuesday, December 1, 2015 at 9:30 ... and Presentations." Please connect to the website at least 15 ...
Breaking Biology Technology:
(Date:10/26/2015)... and LAS VEGAS , ... Nok Labs , an innovator in modern authentication and ... today announced the launch of its latest version of ... platform enabling organizations to use standards-based authentication that supports ... Nok S3 Authentication Suite is ideal for organizations deploying ...
(Date:10/23/2015)... California , October 23, 2015 ... (SMI) announce a mobile plug and play integration of ... real-world tasks SensoMotoric Instruments (SMI) present ... wearable solutions for eye tracking and physiological data registration. ... SMI Eye Tracking Glasses 2w and physiological ...
(Date:10/22/2015)... 2015 About fingerprint biometrics ... individual with the database to identify and verify an ... loop. Pattern-based algorithms are used to match an individual,s ... was introduced in 1986, which is being used by ... criminal. Technavio,s analysts forecast the global fingerprint ...
Breaking Biology News(10 mins):